Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 10/20 | 0.50 |
| ▸ | CTSK | P43235 | 9/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 6/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305190 | 1.00 | CTSS (0.50) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL755894 | 1.00 | CTSS (0.50) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL7330819 | 0.91 | CTSK (0.44) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL15582702 | 0.87 | CTSS (0.48) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL1688920 | 0.87 | CTSK (0.47) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL3735030 | 0.87 | CTSK (0.47) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL12973256 | 0.87 | CTSK (0.47) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL3733285 | 0.87 | CTSK (0.47) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL16000767 | 0.87 | CTSK (0.47) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL16343552 | 0.86 | CTSK (0.46) | CTSSCTSKCTSLCTSBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4440563-A1 | COMPOSITIONS AND METHODS USING AN AMINO ACID BLEND FOR PROVIDING A HEALTH BENEFIT IN AN ANIMAL | Société des Produits Nestlé S.A. (CH) | 2024-10-09 | — | — | EP | claimed |
| EP-4259120-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND AT LEAST ONE LARGE NEUTRAL AMINO ACID AND/OR CATIONIC AMINO ACID OR PRECURSOR THEREOF | Société des Produits Nestlé S.A. (CH) | 2023-10-18 | — | — | EP | claimed |
| CN-112778162-B | Preparation method of chiral beta- (Boc-amino) -5-hexynoic acid | 上海海皋科技有限公司 | 2023-06-16 | — | — | CN | claimed |
| WO-2023100077-A1 | COMPOSITIONS AND METHODS USING AN AMINO ACID BLEND FOR PROVIDING A HEALTH BENEFIT IN AN ANIMAL | SOCIETE DES PRODUITS NESTLE SA (CH) | 2023-06-08 | — | — | WO | claimed |
| WO-2022122730-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND AT LEAST ONE LARGE NEUTRAL AMINO ACID AND/OR CATIONIC AMINO ACID OR PRECURSOR THEREOF | Société des Produits Nestlé S.A. (CH) | 2022-06-16 | — | — | WO | claimed |
| CN-112778162-A | Preparation method of chiral beta- (Boc-amino) -5-hexynoic acid | 上海海皋科技有限公司 | 2021-05-11 | — | — | CN | claimed |
| EP-4615434-A1 | COMPOSITIONS AND METHODS USING GLYCINE TO REDUCE BIOLOGICAL AGE OF AN ADULT ANIMAL | Société des Produits Nestlé S.A. (CH) | 2025-09-17 | — | — | EP | disclosed |
| EP-4440563-A1 | COMPOSITIONS AND METHODS USING AN AMINO ACID BLEND FOR PROVIDING A HEALTH BENEFIT IN AN ANIMAL | Société des Produits Nestlé S.A. (CH) | 2024-10-09 | — | — | EP | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024099883-A1 | COMPOSITIONS AND METHODS USING GLYCINE TO REDUCE BIOLOGICAL AGE OF AN ADULT ANIMAL | Société des Produits Nestlé S.A. (CH) | 2024-05-16 | — | — | WO | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| EP-4259120-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND AT LEAST ONE LARGE NEUTRAL AMINO ACID AND/OR CATIONIC AMINO ACID OR PRECURSOR THEREOF | Société des Produits Nestlé S.A. (CH) | 2023-10-18 | — | — | EP | disclosed |
| CN-112778162-B | Preparation method of chiral beta- (Boc-amino) -5-hexynoic acid | 上海海皋科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| US-7399766-B2 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060142581-A1 | Hetero substitued sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-20060040954-A1 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142581-A1 | Hetero substitued sodium channel blockers | SCN2B, CACNA1B, CACNA1G | CTSS 4492/4885CTSK 4380/4885CTSL 4544/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | CTSS 1105/4885CTSK 2645/4885CTSL 912/4885 |
| US-20060040954-A1 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | SCN2A, CACNA1B, HCN4 | CTSS 3583/4885CTSK 3600/4885CTSL 3027/4885 |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | KCNN2, KCNN1, KCNN3 | CTSS 1323/4885CTSK 1945/4885CTSL 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.